The Diagnostic Performance of Cr/CysC for Sarcopenia and Its Predictive Value on Clinical Outcomes in Hospitalized Older Patients: a Prospective Cohort Study

Overview

Journal Eur Geriatr Med

Specialty Geriatrics

Date 2024 Feb 23

PMID 38393457

Authors

Xiangping Tu

Taiping Lin

Li Huang

Tianjiao Tang

Dongmei Xie

Langli Gao

Tingting Jiang

Jirong Yue

Affiliations

Soon will be listed here.

Abstract

Purpose: The utilization of the creatinine-to-cystatin C ratio (Cr/CysC) represents an innovative method for predicting sarcopenia. Our objectives encompassed the evaluation of sarcopenia diagnostic accuracy for Cr/CysC, SARC-F, SARC-CalF, the combination of Cr/CysC and SARC-CalF, and the Ishii score, as well as an exploration of the predictive value of Cr/CysC concerning clinical outcomes within hospitalized older individuals.

Methods: We employed receiver operating characteristic (ROC) curves and calculated areas under the curves (AUCs) to assess the diagnostic accuracy. Furthermore, we applied univariate and multivariate Cox proportional-hazard models to calculate the hazard ratio (HR) and 95% confidence interval (CI) of risk factors affecting prognosis.

Results: Our study included 312 participants, comprising 167 men and 145 women, with an average age of 71 years. Among males, the AUCs for Cr/CysC, SARC-F, SARC-CalF, the combination of Cr/CysC and SARC-CalF, and the Ishii score were 0.717 [95% CI 0.642-0.784], 0.669 (95% CI 0.592-0.739), 0.845 (95% CI 0.781-0.896), 0.882 (95% CI 0.823-0.926), and 0.938 (95% CI 0.890-0.969), respectively. In females, the AUCs for Cr/CysC, SARC-F, SARC-CalF, the combination of Cr/CysC and SARC-CalF, and the Ishii score were 0.706 (95% CI 0.625-0.779), 0.631 (95% CI 0.547-0.710), 0.763 (95% CI 0.686-0.830), 0.789 (95% CI 0.714-0.853), and 0.898 (95% CI 0.837-0.942), respectively. After adjusting for age, sex, physical exercise, smoking, drinking, hypertension, coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), and cancer, sarcopenia identified by Cr/CysC (adjusted HR = 2.176, 95% CI 1.062-4.460, P = 0.034) was independently associated with poor overall survival in hospitalized older patients.

Conclusions: Cr/CysC has satisfactory diagnostic accuracy for sarcopenia diagnosis and predictive value for poor outcomes in hospitalized older patients. The combination of Cr/CysC and SARC-CalF may provide a more accurate screening for sarcopenia and the Ishii score may be the most accurate clinical method for detecting sarcopenia.

Citing Articles

Correlation of lung function and sarcopenia in elderly patients with chronic obstructive pulmonary disease and analysis of factors influencing sarcopenia.

Yang X, Wei Y, Zhao J, Bai Y Am J Transl Res. 2025; 17(1):358-376.

PMID: 39959237 PMC: 11826181. DOI: 10.62347/OGUT1532.

Sex differences in the association between sarcopenia index and sarcopenia: a cross-sectional study from a Chinese community-based population.

Yang H, Huang Y, Jiang G, Duan Z, Du R, Hao Y Eur Geriatr Med. 2024; 16(1):55-65.

PMID: 39623162 PMC: 11850426. DOI: 10.1007/s41999-024-01111-w.

References

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

Norman K, Otten L . Financial impact of sarcopenia or low muscle mass - A short review. Clin Nutr. 2018; 38(4):1489-1495. DOI: 10.1016/j.clnu.2018.09.026. View

Janssen I, Shepard D, Katzmarzyk P, Roubenoff R . The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2003; 52(1):80-5. DOI: 10.1111/j.1532-5415.2004.52014.x. View

Petermann-Rocha F, Balntzi V, Gray S, Lara J, Ho F, Pell J . Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2021; 13(1):86-99. PMC: 8818604. DOI: 10.1002/jcsm.12783. View

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

Chen L, Liu L, Woo J, Assantachai P, Auyeung T, Bahyah K . Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15(2):95-101. DOI: 10.1016/j.jamda.2013.11.025. View

Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412-23. PMC: 2886201. DOI: 10.1093/ageing/afq034. View

Fielding R, Vellas B, Evans W, Bhasin S, Morley J, Newman A . Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011; 12(4):249-56. PMC: 3377163. DOI: 10.1016/j.jamda.2011.01.003. View

Studenski S, Peters K, Alley D, Cawthon P, McLean R, Harris T . The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014; 69(5):547-58. PMC: 3991146. DOI: 10.1093/gerona/glu010. View

10.

Yin M, Zhang H, Liu Q, Ding F, Deng Y, Hou L . Diagnostic Performance of Clinical Laboratory Indicators With Sarcopenia: Results From the West China Health and Aging Trend Study. Front Endocrinol (Lausanne). 2021; 12:785045. PMC: 8702640. DOI: 10.3389/fendo.2021.785045. View

11.

Sayer A, Cruz-Jentoft A . Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022; 51(10). PMC: 9588427. DOI: 10.1093/ageing/afac220. View

12.

Beaudart C, McCloskey E, Bruyere O, Cesari M, Rolland Y, Rizzoli R . Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016; 16(1):170. PMC: 5052976. DOI: 10.1186/s12877-016-0349-4. View

13.

Malmstrom T, Miller D, Simonsick E, Ferrucci L, Morley J . SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1):28-36. PMC: 4799853. DOI: 10.1002/jcsm.12048. View

14.

Cruz-Jentoft A, Sayer A . Sarcopenia. Lancet. 2019; 393(10191):2636-2646. DOI: 10.1016/S0140-6736(19)31138-9. View

15.

Bahat G, Erdogan T, Ilhan B . SARC-F and other screening tests for sarcopenia. Curr Opin Clin Nutr Metab Care. 2021; 25(1):37-42. DOI: 10.1097/MCO.0000000000000801. View

16.

Barbosa-Silva T, Menezes A, Bielemann R, Malmstrom T, Gonzalez M . Enhancing SARC-F: Improving Sarcopenia Screening in the Clinical Practice. J Am Med Dir Assoc. 2016; 17(12):1136-1141. DOI: 10.1016/j.jamda.2016.08.004. View

17.

Ishii S, Tanaka T, Shibasaki K, Ouchi Y, Kikutani T, Higashiguchi T . Development of a simple screening test for sarcopenia in older adults. Geriatr Gerontol Int. 2014; 14 Suppl 1:93-101. DOI: 10.1111/ggi.12197. View

18.

Tang T, Xie L, Hu S, Tan L, Lei X, Luo X . Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2022; 13(3):1800-1810. PMC: 9178169. DOI: 10.1002/jcsm.12977. View

19.

Cartin-Ceba R, Afessa B, Gajic O . Low baseline serum creatinine concentration predicts mortality in critically ill patients independent of body mass index. Crit Care Med. 2007; 35(10):2420-3. DOI: 10.1097/01.ccm.0000281856.78526.f4. View

20.

Randers E, Erlandsen E . Serum cystatin C as an endogenous marker of the renal function--a review. Clin Chem Lab Med. 1999; 37(4):389-95. DOI: 10.1515/CCLM.1999.064. View